Drugs / CPX101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06545162 | Dec 2024 → Dec 2025 | — | Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06532578 | Aug 2024 → Dec 2025 | morbid obesity | Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPX101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545162 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of CPX101 or placebo” NCT06532578 ↗ |